Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin
Authors:
- Harold E. BaysHBHarold E. Bays
- Ronald B. GoldbergRGRonald B. Goldberg
- Kenneth E. TruittKTKenneth E. Truitt
- Michael R. JonesMJMichael R. Jones
Open Access
- 13 October 2008
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 168 (18) , 1975-1983
Abstract
Colesevelam hydrochloride is a bile acid sequestrant that was approved as a cholesterol-lowering agent in the United States in 2000 and approved in January 2008 to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).1 A pilot study suggested that colesevelam improved glycemic control in patients with T2DM, resulting in a mean reduction in hemoglobin A1c (HbA1c) level of 0.5% compared with placebo (P = .007).2 Furthermore, in patients with T2DM with a higher baseline HbA1c level (≥8.0%), colesevelam reduced mean HbA1c level by 1.0% (P = .002 vs placebo).2 The present report describes a larger trial to assess the efficacy and safety of colesevelam for improving glycemic control in patients with T2DM not adequately controlled by a stable regimen of metformin-based therapy.Keywords
This publication has 8 references indexed in Scilit:
- Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitusCurrent Medical Research and Opinion, 2007
- The nuclear receptor LXR is a glucose sensorNature, 2006
- Effects of Colesevelam Hydrochloride (WelChol) on Biomarkers of Inflammation in Patients With Mild HypercholesterolemiaThe American Journal of Cardiology, 2006
- Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering EfficacyDiabetes Care, 2006
- Effects of Colesevelam Hydrochloride on Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein When Added to Statins in Patients With HypercholesterolemiaThe American Journal of Cardiology, 2006
- Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed DiabetesJAMA, 2004
- Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissueProceedings of the National Academy of Sciences, 2003
- Cholestyramine Therapy for Dyslipidemia in Non–Insulin-dependent Diabetes Mellitus: A Short-Term, Double-Blind, Crossover TrialAnnals of Internal Medicine, 1994